CARA logo

Cara Therapeutics (CARA)

Profile

Full Name

Cara Therapeutics, Inc.

Ticker Symbol

CARA

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

January 31, 2014

Indexes

Not included

Website

http://www.caratherapeutics.com

Employees

10

Key Details

Price

$5.55(+13.26%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$7.14M(-65.96% YoY)

Annual EPS

-$15.53(+40.86% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$5.55
CARA price is $5.55

30-Day Relative Volume

5.60
CARA 30-day relative volume is 5.60

Price Performance

Price Most recent change

+13.26%
CARA price was up +13.26% on Apr 14, 2025

Price YTD change

-9.32%
CARA price is down -9.32% since January 1st

Price 1-year change

-39.46%
CARA price is down -39.46% year-on-year

Price 3-year change

-96.66%
CARA price is down -96.66% over the past 3 years

Price Range

Price All-time high

$350.28
CARA price is currently -98.42% below its historical high of $350.28

Price 3-year low

$0.24
CARA price is currently +2212.46% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$25.38M
CARA market capitalization is $25.38 million

Market cap 3-year change

-96.58%
CARA market capitalization is down -96.58% over the past 3 years

Market cap All-time high

$1.46B
CARA market capitalization is currently -98.26% below its historical high of $1.46 billion

Market cap sector rank

29.83%
CARA market capitalization is higher than 29.83% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.4%
CARA shares outstanding is up +0.4% year-on-year

Shares Outstanding 3-Year Change

+2.41%
CARA shares outstanding is up +2.41% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.37
CARA beta is 0.37

200-day SMA

$4.20
CARA price is currently +32.06% above its 200-day simple moving average

50-day SMA

$5.05
CARA price is currently +9.81% above its 50-day simple moving average

RSI

62.26
CARA 14-day relative strength index is 62.26

Volume

5.60
CARA 30-day relative volume is 5.60

ATR

$0.30
CARA average true range is $0.30

10-day Historical Volatility

76.29%
CARA 10-day historical volatility is 76.29%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$7.14M
CARA annual revenue is $7.14 million

Revenue Analysts estimate

$3.60M
CARA annual revenue is currently +98.25% higher than the consensus analysts' forecast

Revenue 1-year change

-65.96%
CARA annual revenue is down -65.96% year-on-year

Revenue Sector rank

24.08%
CARA annual revenue is higher than 24.08% of companies in Healthcare sector

EPS

EPS

-$15.53
CARA annual earnings per share is -$15.53

EPS Analysts estimate

-
CARA annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

+40.86%
CARA annual earnings per share is up +40.86% year-on-year

EPS Sector rank

8.85%
CARA annual earnings per share is higher than 8.85% of companies in Healthcare sector

Profit

Gross profit

$6.52M
CARA annual gross profit is $6.52 million

Gross margin

91.31%
CARA annual gross profit margin is 91.31%

Operating profit

-$52.82M
CARA annual operating income is -$52.82 million

Operating margin

-740.06%
CARA annual operating profit margin is -740.06%

Net income

-$70.87M
CARA annual net profit is -$70.87 million

Net margin

-992.95%
CARA annual net profit margin is -992.95%

Expenses

Total expenses

$59.95M
CARA annual total expenses is $59.95 million

Operating expenses

$59.34M
CARA annual total operating expenses is $59.34 million

Cost of goods sold

$620.00K
CARA annual cost of goods sold is $620.00 thousand

Selling, general & administrative expenses

$26.39M
CARA annual SGA is $26.39 million

Depreciation and amortization

$192.00K
CARA annual depreciation & amortization is $192.00 thousand

Interest expense

$8.47M
CARA annual interest expense is $8.47 million

Income tax

-$398.00K
CARA annual income tax is -$398.00 thousand

EBIT & EBITDA

EBIT

-$62.79M
CARA annual earnings before interest & taxes is -$62.79 million

EBITDA

-$62.60M
CARA annual EBITDA is -$62.60 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$43.83M
CARA annual total assets is $43.83 million

Non current assets

$0.00
CARA annual long term assets is $0.00

Current assets

$43.83M
CARA annual total current assets is $43.83 million

Cash and cash equivalents

$37.90M
CARA annual cash & cash equivalents is $37.90 million

Accounts receivable

$407.00K
CARA annual accounts receivable is $407.00 thousand

Inventory

$900.00K
CARA annual inventory is $900.00 thousand

Liabilities

Total liabilities

$48.42M
CARA annual total liabilities is $48.42 million

Long term liabilities

$44.45M
CARA annual total long term liabilities is $44.45 million

Current liabilities

$3.97M
CARA annual total current liabilities is $3.97 million

Accounts payable

$1.43M
CARA annual accounts payable is $1.43 million

Debt

Total debt

$0.00
CARA annual total debt is $0.00

Total debt 1-year change

-100%
CARA annual total debt is down -100% year-on-year

Long term debt

$0.00
CARA annual long term debt is $0.00

Short term debt

-
CARA annual short term debt value is unknown

Equity & Capital

Shareholders equity

-$4.59M
CARA annual stockholders equity is -$4.59 million

Book value

-$4.59M
CARA annual book value is -$4.59 million

Retained earnings

-$755.61M
CARA annual retained earnings is -$755.61 million

Working capital

$39.85M
CARA annual working capital is $39.85 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$60.92M
CARA annual cash flow from operations is -$60.92 million

Cash from operations 1-year change

+33.84%
CARA annual cash flow from operations is up +33.84% year-on-year

Cash from investing

$48.74M
CARA annual cash flow from investing activities is $48.74 million

Cash from investing 1-year change

+12.15%
CARA annual cash flow from investing activities is up +12.15% year-on-year

Cash from financing

-$3.60M
CARA annual cash flow from financing activities is -$3.60 million

Cash from financing 1-year change

-109.45%
CARA annual cash flow from financing activities is down -109.45% year-on-year

CAPEX

CAPEX

$1.05M
CARA annual capital expenditures is $1.05 million

CAPEX 1-year change

-55.96%
CARA annual capital expenditures is down -55.96% year-on-year

Free Cash Flow

Free cash flow

-$61.96M
CARA annual free cash flow is -$61.96 million

Free cash flow 1-year change

+34.4%
CARA annual free cash flow is up +34.4% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

91.31%
CARA annual gross profit margin is 91.31%

Operating margin

-740.06%
CARA annual operating profit margin is -740.06%

Net margin

-992.95%
CARA annual net profit margin is -992.95%

ROA & ROE

ROA

-83.53%
CARA annual return on assets is -83.53%

ROE

-270.01%
CARA annual return on equity is -270.01%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CARA price to earnings ratio value is unknown

PE ratio Sector rank

-
CARA price to earnings ratio is unknown

PB Ratio

PB ratio

-5.53
CARA price to book ratio is -5.53

PB ratio Sector rank

3.29%
CARA price to book ratio is higher than 3.29% of companies in Healthcare sector

PS Ratio

PS ratio

3.56
CARA price to sales ratio is 3.56

PS ratio Sector rank

57.82%
CARA price to sales ratio is higher than 57.82% of companies in Healthcare sector

Enterprise value

Enterprise value

-$12.52M
CARA enterprise value is -$12.52 million

Enterprise value Sector rank

4.13%
CARA enterprise value is higher than 4.13% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.20
CARA EV/EBITDA is 0.20

EV/EBITDA Sector rank

69.24%
CARA EV/EBITDA is higher than 69.24% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

11.03
CARA annual current ratio is 11.03

Quick ratio

10.81
CARA annual quick ratio is 10.81

Leverage

Debt to equity

0.00
CARA annual debt to equity ratio is 0.00

Interest coverage ratio

-7.41
CARA annual interest coverage ratio is -7.41

Risk & Stability

Piotroski F-Score

-
CARA piotroski f-score value is unknown

Altman Z-Score

-27.30
CARA altman z-score is -27.30

Analyst ratings

Recent major analysts updates

Jun 13, 24 Needham
Hold
Jun 13, 24 HC Wainwright & Co.
Neutral
Jun 13, 24 Canaccord Genuity
Hold
May 23, 24 Needham
Buy
May 15, 24 HC Wainwright & Co.
Buy
May 14, 24 Needham
Buy
Apr 10, 24 Needham
Buy
Mar 6, 24 Canaccord Genuity
Buy
Mar 5, 24 Needham
Buy
Jan 22, 24 Needham
Buy

Institutional Ownership

Similar stocks

NRSN logo
NeuroSense Therapeutics (NRSN)
GBIO logo
Generation Bio Co (GBIO)
POCI logo
Precision Optics (POCI)
DARE logo
Dare Bioscience (DARE)
PYPD logo
PolyPid (PYPD)
LEXX logo
Lexaria Bioscience (LEXX)
DOMH logo
Dominari Holdings (DOMH)
TPST logo
Tempest Therapeutics (TPST)
CGTX logo
Cognition Therapeutics (CGTX)
  • What is the ticker symbol for Cara Therapeutics?
  • Does Cara Therapeutics pay dividends?
  • What sector is Cara Therapeutics in?
  • What industry is Cara Therapeutics in?
  • What country is Cara Therapeutics based in?
  • When did Cara Therapeutics go public?
  • Is Cara Therapeutics in the S&P 500?
  • Is Cara Therapeutics in the NASDAQ 100?
  • Is Cara Therapeutics in the Dow Jones?
  • When was Cara Therapeutics's last earnings report?
  • When does Cara Therapeutics report earnings?
  • Should I buy Cara Therapeutics stock now?

What is the ticker symbol for Cara Therapeutics?

The ticker symbol for Cara Therapeutics is NASDAQ:CARA

Does Cara Therapeutics pay dividends?

No, Cara Therapeutics does not pay dividends

What sector is Cara Therapeutics in?

Cara Therapeutics is in the Healthcare sector

What industry is Cara Therapeutics in?

Cara Therapeutics is in the Biotechnology industry

What country is Cara Therapeutics based in?

Cara Therapeutics is headquartered in United States

When did Cara Therapeutics go public?

Cara Therapeutics's initial public offering (IPO) was on January 31, 2014

Is Cara Therapeutics in the S&P 500?

No, Cara Therapeutics is not included in the S&P 500 index

Is Cara Therapeutics in the NASDAQ 100?

No, Cara Therapeutics is not included in the NASDAQ 100 index

Is Cara Therapeutics in the Dow Jones?

No, Cara Therapeutics is not included in the Dow Jones index

When was Cara Therapeutics's last earnings report?

Cara Therapeutics's most recent earnings report was on Nov 14, 2024

When does Cara Therapeutics report earnings?

The next expected earnings date for Cara Therapeutics is May 13, 2025

Should I buy Cara Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page